Beyond ARPIs - Optimizing Sequencing, Safety Management, and Shared Decision Making in Later-Line mCRPC
Prostate cancer remains one of the most significant oncologic challenges in the United States, with an estimated 322,000 new cases projected in 2026 and approximately 3.4 million men currently living with the disease. Despite initial responses to androgen deprivation therapy, nearly all patients with metastatic disease will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), with a median overall survival of approximately two years. The therapeutic landscape for mCRPC has expanded significantly over the past two decades. The very breadth of available agents has introduced substantial complexity into clinical decision-making, particularly when choosing second-line and later therapies. Clinicians now face the challenge of choosing among multiple agents with distinct mechanisms of action, different toxicity profiles, and varying levels of evidence in heavily pretreated populations. This educational initiative establishes impactful expert-led small group interactions among highly qualified community oncologists, urologists, APPs, nurses, pharmacists, fellows, and other members of the care team involved in the treatment of patients with mCRPC that will, through a variety of collaborative educational experiences, help them optimize the care provided to these patients. <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Optimizing Treatment for Patients with CLL
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
PARP-Combination Therapy in the Community Setting: Practical Integration into Routine Care
PARP inhibitor–based combinations are expanding treatment options for patients with metastatic prostate cancer, but integrating these therapies into community practice requires appropriate biomarker and genetic testing, careful evaluation of clinical trial evidence, and proactive management of treatment-related adverse events. This collaborative social learning activity brings together urologists, medical oncologists, APPs, pharmacists, nurses, fellows, and other members of the prostate cancer care team to explore best practices in molecular testing, assess the evolving evidence for PARP inhibitor combinations, and apply practical strategies for managing associated toxicities. Through independent learning and case-based peer discussion, participants will exchange real-world insights and strengthen the integration of PARP-combination therapy into routine patient care..<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Adjuvant Therapy in HR+/HER2- Breast Cancer: Choosing and Managing CDK4/6 Inhibitors for Real-World Patients
Early-stage hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common breast cancer subtype, accounting for roughly two-thirds to three-quarters of all new breast cancer cases in the United States (U.S.). Endocrine therapy (ET) has long been the backbone of adjuvant treatment for HR+ breast cancer, substantially reducing recurrence risk. However, many high-risk patients still develop resistance and/or relapse with ET, highlighting the need for new strategies. In the metastatic setting, combining ET with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (e.g., abemaciclib, palbociclib, ribociclib) revolutionized care by markedly improving progression-free and overall survival with a tolerable safety profile. This success spurred trials testing CDK4/6 inhibitors as adjuvant therapy in early disease to further reduce recurrences. Recent landmark trials have indeed shown that adding a CDK4/6 inhibitor to ET can improve invasive disease-free survival in high-risk early breast cancer, representing a major advance in curative therapy. This educational initiative establishes impactful small group interactions among highly qualified oncologists, oncology APPs, and oncology nurses that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with HR+/HER2- breast cancer.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Beyond Clinical Trials: Addressing Real-World Evidence and Challenges in Multiple Myeloma Immunotherapy
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains incurable, and most patients eventually relapse even after achieving remission. Each successive relapse is harder to treat: response rates drop and remission durations shorten with later treatment lines. Given the importance of RWE in RRMM treatment, clinicians treating these patients should be informed about current RWE publications. This educational initiative establishes impactful small group interactions among hematology/oncology clinicians that will provide the opportunity to comprehensively review, discuss and reflect on RWE related to RRMM and how it may impact the care of their patients. Specifically, during this experience, clinicians will explore a number of important issues related to RWE in RRMM including: a) efficacy disparities between clinical trial data and RWE; b) patient population differences; c) safety profile variations; d) treatment sequencing results; e) integration of novel therapies; and f) identifying optimal therapies for specific patient types.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
New Perspectives in the Front-line Treatment of Metastatic Bladder Cancer
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
New Frontiers with BCMA Targeting in the Treatment of Heavily Relapsed Multiple Myeloma
Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
How MS Care Has Evolved Since the COVID-19 Pandemic
As a result of the COVID-19 pandemic, we have learned valuable lessons pertinent to MS care. This includes knowledge about COVID-19 severity and infection risk (especially as it relates to DMT selection), a much greater understanding of how DMTs affect SARS-CoV-2 vaccine responses, ways to potentially optimize vaccine responses, and the role of telemedicine. This program covers some of these major lessons learned about MS care. The Gather-ed collaborative social learning platform establishes a network of providers who can support each other with the goal of learning and sharing best practices that will improve outcomes for patients with MS.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Unlocking the Gaps to Improve SMA Outcomes
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments may help patients live longer, creating unique clinical needs. Adults now make up more than a quarter of patients with SMA. However, there are no specific guidelines for the assessment and treatment of adult patients, leading to gaps in their diagnosis and management. Adult care is complex and requires multidisciplinary care. This collaborative CME provides the opportunity to learn and share best practices that will improve outcomes for patients with SMA.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
